Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelfinavir plus MLN9708 in advanced solid tumors or lymphoma
NCT03422874Phase 1Withdrawn
- Sponsor
- Dartmouth Health
- Start
- Aug 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ixazomib and nelfinavir in solid tumor and lymphoma, sponsored by Dartmouth Health. Primary endpoints: Maximum Tolerated Dose of nelfinavir at 1 year and Toxicity of MLN9708 when combined with nelfinavir at 24 months. Planned start Aug 2016; status: withdrawn.
02
Drugs
ixazomibnelfinavir
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03422874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03422874.